Literature DB >> 15181135

PET for the evaluation of pleural thickening observed on CT.

Henk Kramer1, Remge M Pieterman, Dirk-Jan Slebos, Wim Timens, Willem Vaalburg, Gerard H Koëter, Harry J M Groen.   

Abstract

UNLABELLED: Early discrimination between benign and malignant pleural diseases is vital for the treatment and prognosis of a patient. Imaging is traditionally performed with CT or MRI, with an accuracy of 50%-75%. PET has proven to be superior as a diagnostic tool in several malignancies. In this prospective study, PET results in patients with pleural abnormalities on CT were compared with histologic results.
METHODS: Eligible patients had pleural thickening on CT and were medically fit for surgical diagnostic procedures. All patients underwent PET. Qualitative assessment led to a PET score of 1 (definitely normal), 2 (probably normal), 3 (probably abnormal), or 4 (definitely abnormal). PET scores of 1 or 2 indicated a negative PET finding, whereas PET scores of 3 or 4 indicated a positive PET finding. Pathologic verification techniques included thoracocentesis, thoracoscopy, or open pleural biopsy at thoracotomy.
RESULTS: Thirty-two patients were enrolled, 19 with malignant and 13 with benign pleural disease. PET was true positive in 18 and true negative in 12 patients, with an accuracy and negative predictive value of 94% and 92%, respectively. PET was false negative in a patient with a slowly growing malignant solitary fibrous tumor and false positive in a patient with infectious pleuritis. Median standardized uptake values calculated for 7 patients with malignant and benign pleural diseases were 6.28 and 1.69, respectively. Patients with a PET score of 1 or 2 survived significantly longer than patients with a PET score of 3 or 4.
CONCLUSION: Qualitative assessment of pleural thickening with PET accurately discriminates between malignant and benign pleural thickening, with a high accuracy and negative predictive value.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181135

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  PET: other thoracic malignancies.

Authors:  Leslie E Quint
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

2.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

3.  Positron emission tomography in mesothelioma patients.

Authors:  Gaia Grassetto; Domenico Rubello
Journal:  Mol Imaging Biol       Date:  2009-03-25       Impact factor: 3.488

4.  Unusual Contiguous Soft Tissue Spread of Advanced Malignant Mesothelioma Detected by FDG PET/CT.

Authors:  Yuyang Zhang; Jamie Edwards; Hadyn Williams; Zhonglin Hao; Samir Khleif; Darko Pucar
Journal:  Nucl Med Mol Imaging       Date:  2016-06-06

Review 5.  Solitary fibrous tumor: an update on the spectrum of extrapleural manifestations.

Authors:  Francis N Musyoki; Ayoub Nahal; Thomas I Powell
Journal:  Skeletal Radiol       Date:  2010-10-16       Impact factor: 2.199

6.  Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.

Authors:  Seiji Kurata; Masatoshi Ishibashi; Koichi Azuma; Hayato Kaida; Shinzo Takamori; Kiminori Fujimoto; Maiko Kobayashi; Yasumitsu Hirose; Hisamichi Aizawa; Naofumi Hayabuchi
Journal:  Jpn J Radiol       Date:  2010-07-27       Impact factor: 2.374

7.  Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.

Authors:  Ayse Mavi; Sandip Basu; Tevfik F Cermik; Muammer Urhan; Mehdi Bathaii; Dhurairaj Thiruvenkatasamy; Mohamed Houseni; Simin Dadparvar; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2009-05-27       Impact factor: 3.488

Review 8.  Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

9.  HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.

Authors:  Tapan K Nayak; Kayhan Garmestani; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

10.  Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma.

Authors:  Tsutomu Shinohara; Naoki Shiota; Motohiko Kume; Norihiko Hamada; Keishi Naruse; Fumitaka Ogushi
Journal:  BMC Infect Dis       Date:  2013-01-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.